Gounder Prabhu P, Zulz Tammy, Desai Shalini, Stenz Flemming, Rudolph Karen, Tsang Raymond, Tyrrell Gregory J, Bruce Michael G
Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, AK, USA.
Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, AK, USA.
J Infect. 2015 Aug;71(2):179-87. doi: 10.1016/j.jinf.2015.04.001. Epub 2015 Apr 10.
To determine the incidence of meningitis caused by Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae in the North American Arctic during 2000-2010.
Surveillance data were obtained from the International Circumpolar Surveillance network. We defined a case of bacterial meningitis caused by H. influenzae, N. meningitidis, or S. pneumoniae as a culture-positive isolate obtained from a normally sterile site in a resident with a meningitis diagnosis.
The annual incidence/100,000 persons for meningitis caused by H. influenzae, N. meningitidis, and S. pneumoniae among all North American Arctic residents was: 0.6, 0.5, and 1.5, respectively; the meningitis incidence among indigenous persons in Alaska and Canada (indigenous status not recorded in Greenland) for those three bacteria was: 2.1, 0.8, and 2.4, respectively. The percentage of pneumococcal isolates belonging to a 7-valent pneumococcal conjugate vaccine serotype declined from 2000-2004 to 2005-2010 (31%-2%, p-value <0.01). During 2005-2010, serotype a caused 55% of H. influenzae meningitis and serogroup B caused 86% of meningococcal meningitis.
Compared with all North American Arctic residents, indigenous people suffer disproportionately from bacterial meningitis. Arctic residents could benefit from the development of an H. influenzae serotype a vaccine and implementation of a meningococcal serogroup B vaccine.
确定2000 - 2010年北美北极地区由流感嗜血杆菌、脑膜炎奈瑟菌和肺炎链球菌引起的脑膜炎发病率。
监测数据来自国际环北极监测网络。我们将由流感嗜血杆菌、脑膜炎奈瑟菌或肺炎链球菌引起的细菌性脑膜炎病例定义为从诊断为脑膜炎的居民的正常无菌部位获得的培养阳性分离株。
北美北极地区所有居民中,由流感嗜血杆菌、脑膜炎奈瑟菌和肺炎链球菌引起的脑膜炎的年发病率/10万人分别为:0.6、0.5和1.5;阿拉斯加和加拿大(格陵兰未记录原住民身份)原住民中这三种细菌引起的脑膜炎发病率分别为:2.1、0.8和2.4。属于7价肺炎球菌结合疫苗血清型的肺炎球菌分离株的百分比从2000 - 2004年到2005 - 2010年有所下降(31% - 2%,p值<0.01)。在2005 - 2010年期间,a血清型导致了55%的流感嗜血杆菌脑膜炎,B血清群导致了86%的脑膜炎奈瑟菌脑膜炎。
与所有北美北极地区居民相比,原住民患细菌性脑膜炎的比例过高。北极地区居民可能会从流感嗜血杆菌a血清型疫苗的研发和脑膜炎奈瑟菌B血清群疫苗的实施中受益。